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Abstract
Introduction: Measuring thyroid stimulating hormone levels alone may be insufficient to
appropriately evaluate thyroid function. Reduced thyroid stimulating hormone levels associated
to normal/reduced FT4 levels should prompt investigation of pituitary function, on suspicion of
hypopituitarism. Pituitary macroadenomas are the most common cause of hypopituitarism; among
these, macroprolactinomas are usually treated with dopamine-agonist therapy. Hypopituitarism does
not preclude the development of primary hyperthyroidism. This report describes the case of
a patient with a final diagnosis of macroprolactinoma inducing hypopituitarism, who subsequently
developed hyperthyroidism due to a toxic thyroid nodule.
Case presentation: A 62-year-old man underwent biochemistry and thyroid function assessment
for asthenia. Reduced thyroid stimulating hormone levels were associated to slightly decreased FT4
levels and low-normal FT3 levels; thyroid ultrasonography showed a multinodular goiter. Thyroid
scan with
99mTc-pertechnetate revealed an autonomous left nodule with suppression of the
surrounding parenchyma. Pituitary investigation showed partial hypopituitarism associated to
increased prolactin levels: 182-200 ng/ml. Magnetic resonance imaging revealed a large (2.2 cm)
invasive macroadenoma. To avoid a possible high-dose hook effect, the patient's serum was diluted;
the resulting PRL levels of around 1800 ng/ml prompted the final diagnosis of macroprolactinoma.
Reduced libido and erectile dysfunction were ascertained. In addition to replacement therapy with
L-thyroxine and testosterone, cabergoline was started and was progressively increased to high doses
(4 g/week); this yielded a significant but incomplete reduction of PRL levels (63-99 ng/ml). Sexual
function improved. The macroadenoma shrank over the first two years of therapy, but subsequently
enlarged slightly. Following stereotactic radiosurgery, the tumor stabilized and prolactin almost
normalized (22 ng/ml) on therapy. Over the years, thyroid nodule volume was unmodified, but
hyperthyroidism on L-thyroxine therapy was found, and increased FT3 levels with suppressed thyroid
stimulating hormone levels were confirmed off-therapy. Thyroid scan confirmed the left autonomous
nodule, which was successfully treated with methimazole.
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thyroid hormone levels may be the first clue to unsuspected hypopituitarism. Moderately increased
prolactin levels in the presence of a large macroadenoma warrant serum dilution in order to avoid
a possible hook effect. Stereotactic radiosurgery is a useful non-invasive tool in the management of
pituitary tumors. A pre-toxic thyroid nodule with low secretory activity may initially be masked by
the coexistence of secondary hypothyroidism, but may lead to overt hyperthyroidism over time.
Introduction
Decreased/normal TSH levels associated to low-normal/
reduced free-thyroid hormone levels may be the first sign
of undiagnosed hypopituitarism (HYPO) [1-3]. HYPO is
frequently due to pituitary macroadenomas. Among these,
macroprolactinomas are usually managed by means of
long-acting dopamine agonist therapy [4-6]. Nevertheless,
around 20% of macroprolactinomas are resistant to
medical therapy in terms of both lack of PRL normal-
ization and tumor shrinkage [4-7]. A high-dose hook effect
(the antibody used in the two-site-assays is saturated by
very high PRL levels) should be considered whenever
a huge pituitary adenoma is associated to modestly
increased PRL levels [4]. Tailored stereotactic radiosurgery
usually allows satisfactory non-invasive management of
invasive pituitary adenomas resistant to medical therapy
or not amenable or refractory to surgery, in terms of
hormonal control and volume reduction [8-10]; never-
theless, the results in medically and surgically refractory
prolactinomas are modest [9]. Here, we describe the case
of a patient who was eventually diagnosed as having an
invasive macroprolactinoma, which caused hypopituitar-
ism and was partially resistant to cabergoline; the tumor
was satisfactorily managed through a combination of
medical treatment and radiosurgery. Over the years, the
initial secondary hypothyroidism turned into primary
hyperthyroidism due to a toxic thyroid nodule.
Case presentation
In 1999, a 62-year-old hypertensive Caucasian man was
referred to our out-patient endocrinology clinic following
the finding of reduced TSH levels: 0.1 µU/ml (n.v.
0.27-4.2) associated to slightly decreased FT4 levels: 0.6
ng/dl (n.v. 0.7-1.7) during routine follow-up examina-
tions for asthenia. The general practitioner had advised a
99Tc-pertechnetate thyroid scan, which showed a left
autonomous nodule with inhibition of the surrounding
parenchyma, and a thyroid ultrasonography (USG), which
revealed a multinodular goiter (nodule diameter range:
15-25 mm). The patient’s anamnesis was unremarkable
apart from right cryptorchidism (only the left testis was
palpable in the scrotum). Given the hormonal findings, a
general basal assessment of pituitary function was
performed. This revealed partial hypopituitarism
(HYPO): hypogonadotropic hypogonadism (undetectable
LH <0.5 IU/L and reduced FSH: 1.5 IU/L levels,
undetectable testosterone levels: <0.2 ng/ml (n.v. 3-9))
and confirmed secondary hypothyroidism (reduced TSH
levels: 0.2 µIU/ml associated to slightly decreased FT4
levels: 0.6 (n.v. 0.7-1.7) and low-normal FT3 levels), and
undetectable GH with markedly reduced IGF-I levels:
15 ng/ml (n.v. 100-250 ng/ml for patient’s age). Cortisol
levels were normal: 14 µg/dl, whereas PRL levels were
increased: 182-200 ng/ml (monomeric form) (n.v. 3-20).
Given the clear diagnosis of partial hypopituitarism by
means of baseline hormonal evaluation, dynamic pitui-
tary assessments were not performed. Contrast-enhanced
MRI (magnetic resonance imaging) examination of the
brain showed a large pituitary macroadenoma (vertical
diameter 2.2 cm), which invaded the right cavernous
sinus, the sphenoidal sinus and the optic apparatus
(Figrue 1a). Visual field examination was normal. Owing
to the possible discrepancy between PRL levels and the
volume of the tumor, serial dilution of the patient’s serum
was performed in order to avoid the hook effect, and
a final PRL level of 1773 ng/ml was obtained. A diagnosis
of HYPO secondary to a large macroprolactinoma was
eventually made. A targeted anamnesis ascertained erectile
dysfunction and a reduction in libido over the previous
two years. In agreement with the neurosurgeon, medical
treatment with cabergoline at the initial dose of 1 mg/
week was begun. In addition, replacement therapy with
L-thyroxine (75 µg/day) and parenteral depot testosterone
(250 mg i.m./3 weeks) was started, which normalized FT4
and testosterone levels over time. Fine-needle aspiration
biopsy of thyroid nodules disclosed a cytological pattern
compatible with goiter. PRL levels two months after the
start of therapy were significantly reduced: 377 ng/ml
(D%: -78%) in comparison with the baseline, and MRI
showed a slight shrinkage of the macroadenoma (not
shown). Cabergoline was progressively increased over
time, up to a maximal dosage of 4 mg/week; PRL
levels declined further but did not normalize (range:
63-99 ng/ml). Libido and sexual capability improved.
MRI documented a progressive significant reduction in the
pituitary mass (intrasellar remnant) over the first two years
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slightly(Figure1c)(PRLlevelsatthattimewere99 ng/ml).
Cortisol levels (14-18 µg/dl, normal) and IGF-I levels
(<30 ng/ml, reduced) remained unchanged. The combina-
tion of (slight) tumor enlargement and lack of normal-
ization of PRL levels on medical therapy prompted us to
perform stereotactic radiosurgery (SRS) (total dose 2000
cGy). A few months later, thrombocytopenia occurred
(35000-47000/mm
3). Bone marrow evaluation by means
of iliac bone biopsy showed normal hematopoiesis;
antiplatelet autoantibodies were negative. Thrombocyto-
penia was managed conservatively with short-term corti-
sone therapy. The platelet count increased over time, but
remained low (last value: 98000/mm
3). Over the 5 years
following SRS, PRL levels progressively declined,
approaching normalization (last PRL levels: 22 ng/ml),
on high-dose cabergoline (3 mg/week), and the tumor
volume remained stable (Figure 1d). Since high-dosages of
the dopamine-agonist drug were used, an echocardiogram
was performed; this proved normal. Cortisol levels
Figure 1. Magnetic resonance imaging scans of the pituitary macroadenoma over the years in the patient studied. Contrast-
enhanced coronal T1-weighted magnetic resonance imaging showing a large pituitary macroadenoma (arrow) invading the right
cavernous sinus (a). After one year of cabergoline therapy the adenoma was markedly reduced and the intrasellar remnant
(arrow) was modest (b). After two years of therapy a minimal, but evident, increase in the intrasellar remnant (arrow) was
observed (c). Two years after stereotactic radiosurgery the intrasellar remnant (arrow) was stable (d).
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L-thyroxine replacement therapy. Thyroid USG did not
show significant variations in thyroid nodule volume over
the years. At the end of 2007, thyroid hormone assay on
L-thyroxine 75 µg/day surprisingly showed FT4 levels in
the upper normal range: 1.7 ng/dl (n.v. 0.7-1.7), increased
FT3 levels: 5.8 pg/ml (n.v. 1.8-4.6) and suppressed TSH
levels: <0.01 µIU/ml. The patient also complained of
palpitations. Although L-thyroxine was tapered to 50 µg/
day, FT3 levels were unmodified two months later; the drug
was therefore withdrawn and moderate FT3 (5.4 pg/ml)
hyperthyroidism(withFT4levelsintheuppernormalrange:
1.5 ng/dl) was confirmed; thyroid auto-antibodies and
anti-TSH-receptor antibodies were negative. A thyroid scan
showed the initial picture (seen 8 years earlier) of a left
autonomous nodule (Figure 2). As the patient refused
surgery or radioiodine therapy, low-dose (5 mg/day)
methimazole was started. This normalized FT3 levels,
whereas TSH levels remained low. The patient is scheduled
for regular hormonal and morphological follow-up.
Discussion
HYPO is a rare condition and may be overlooked. The
clinical symptoms may range from subtle and unspecific to
dramatic, as when pituitary apoplexia occurs. Macroadeno-
mas are the most prevalent cause of HYPO, though it is
being increasingly acknowledged that brain damage of
different etiologies (e.g. traumas, aneurysmal subarachnoid
hemorrhage and ischemic stroke) is a significant cause of
hypothalamic-pituitary dysfunction [1]. HYPO is mostly
due to non-secreting macroadenomas; among secreting
tumors, macroprolactinomas are the most common and
are more frequent in men [4,5,7]. These tumors can cause
mass-related symptoms and symptoms related to hypo-
gonadism,whichisusuallydiagnosedlateinmen[4,7].In
our patient, who was eventually diagnosed as having a
huge macroprolactinoma causing HYPO, an impairment
of sexual function was ascertained only by means of a
targeted anamnesis. The final diagnosis was made after
hormonal and morphological investigation following the
finding of reduced TSH levels associated to slightly
reduced FT4. Surprisingly, these findings were associated
to an autonomous thyroid nodule, as revealed by thyroid
scan. PRL levels were only moderately elevated and
associated to a voluminous tumor mass. To avoid a
possiblehigh-dosehookeffect[4],thepatient’sserumwas
appropriately diluted; this strategy revealed final real PRL
levels about ten-fold higher (~1800ng/ml). This is a
crucial point in patient management, since macroprolac-
tinomas, unlike non-secreting macroadenomas, usually
r e s p o n dv e r yw e l lt od o p a m i n e r g i ct h e r a p yi nt e r m so f
volume shrinkage and reduction of PRL levels, thus
obviating the need for surgery in most cases. In our
patient, secondary hypothyroidism and hypogonadism
were successfully treated with replacement therapy,
whereas the macroprolactinoma and related hyperprolac-
tinemia were managed with the long-acting dopamine-
agonist cabergoline. However, high-doses (4 mg/week)
were required in order to obtain a significant, though
incomplete, reduction in PRL levels. Resistance to
dopaminergic therapy occurs in around 10-20% of
prolactinomas and seems to be related to a loss of D2
receptors in tumor lactotrophs [4–7]. In our patient, after
partial shrinkage over the first two years of therapy, the
tumor enlarged. SRS was therefore performed, which
achieved satisfactory control of the tumor over time
(5-year follow-up) and led to almost complete normal-
ization of PRL on cabergoline therapy. Our isolated
finding suggests that SRS can be an effective treatment
for macroprolactinomas that are only partially responsive
to high-dosage dopamine-agonist therapy, and which
enlarge on therapy. Careful initial evaluation (distance of
the tumor margin from optic apparatus) is mandatory in
order to assess the suitability of the technique [8-10].
Literature data show that the efficacy of SRS in the
management of prolactinomas is variable and low
[8–10]; this finding might possibly be related to the use
of dopamine-agonists in these tumors [8-10]. The
occurrence of thrombocytopenia in our patient did not
seemtoberelatedtoSRS.Eightyearsafterthediagnosisof
partialHYPOwithsecondaryhypothyroidism,thepatient
developed moderate hyperthyroidism, which was con-
firmedafterL-thyroxinewithdrawal.ThyroidUSGdidnot
Figure 2. The patient’s last
99mTc-pertechnetate thyroid scan
showing an autonomous left nodule with complete
suppression of the surrounding parenchyma. Thyroid function
assessment showed moderate hyperthyroidism.
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thyroid scan was comparable to the initial one (left
autonomous nodule). Antithyroid drug therapy was
required. A possible explanation for our patient’s thyroid
hormone modification over the years is that a pre-toxic
adenomawithlowsecretoryactivity,initiallymaskedby the
coexistence of secondary hypothyroidism, increased its
secretory activity over time, leading to hyperthyroidism.
Conclusions
Our case highlights the importance of assessing free
thyroid hormones whenever TSH levels are reduced. If
both are reduced, suggesting secondary hypothyroidism, a
thorough investigation of pituitary function for possible
HYPO is warranted. Moderately increased PRL levels
associated to voluminous pituitary tumors require serum
dilution to avoid a possible hook effect and obtain a real
(i.e. much higher) hormone value, which is indicative of
macroprolactinoma. Macroprolactinomas are usually
satisfactorily managed in terms of both tumor volume
and PRL level reduction by long-acting dopamine agonist
therapy. SRS may be a useful tool in those patients with
macroprolactinoma who are resistant to medical therapy
or when neurosurgery fails or the tumor is not amenable
to neurosurgery. Hyperthyroidism secondary to toxic
thyroid adenoma may coexist with hypopituitarism.
Abbreviations
FSH, follicle stimulating hormone; GH, growth hormone;
HYPO, hypopituitarism; IGF-I, Insulin-like growth factor 1;
LH, luteinizing hormone; MRI, magnetic resonance ima-
ging; PRL, prolactin; SRS, stereotactic radiosurgery; TSH,
Thyroid stimulating hormone; USG, ultrasonography.
Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available for
review from the journal’s Editor-in-Chief.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LF and PDM were involved in the medical management of
thepatientandwrotethemanuscript.ARwasinvolvedinthe
evaluation of the patient and examined the morphological
images (MRI) over the years. PC performed stereotactic
neurosurgery. All authors have read and approved the final
manuscript.
References
1. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK,
Ghigo E: Hypopituitarism. Lancet 2007, 369:1461-1470.
2. Preiss D, Todd L, Panarelli M: Diagnosing unsuspected hypopi-
tuitarism in adults from suggestive thyroid function test
results. Ann Clin Biochem 2008, 45:70-75.
3. Nguyen-Michel VH, Schwald N, Hunert S, Chahwakilian A, Debray-
Meignan S: Central hypothyroidism allows discovery of a
pituitary disease in older people. JAGS 2007, 55:630-631.
4. Mancini T, Casanueva FF, Giustina A: Hyperprolactinemia and
prolactinomas. Endocrinol Metab Clin North Am 2008, 37:67-99.
5. Schlechte JA: Long-term management of prolactinomas. J Clin
Endocrinol Metab 2007, 92:2861-2865.
6. Gürlek A, Karavitaki N, Ansorge O, Wass JA: What are the
markers of aggressiveness in prolactinomas. Changes in cell
biology, extracellular matrix components, angiogenesis and
genetic. Eur J Endocrinol 2007, 156:143-I53.
7. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the
treatment of prolactinomas. Endocrine Rev 2006, 27:485-534.
8. Mayberg M, Vermeluen S: Advances in stereotactic radiosurgery
in the treatment of pituitary adenomas. Curr Opin Endocrinol
Diabetes Obes 2007, 14:296-300.
9. Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML:
Gamma-knife radiosurgery for medically and surgically
refractory prolactinomas. Neurosurgery 2006, 59:255-266.
10. Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW: Gamma-knife
radiosurgery as primary treatment for prolactinomas.
J Neurosurg 2000, 93:10-13.
Page 5 of 5
(page number not for citation purposes)
Cases Journal 2009, 2:6449 http://casesjournal.com/casesjournal/article/view/6449
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com